Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk

Lancet

Volumn 351, Issue 9098, 1998, Pages 233-241

  Meade, T W ^a   Wilkes, H C ^b   Kelleher, C C ^b   Roderick, P J ^b   Brennan, P J ^b   Wilson, C W ^b   Howarth, D J ^b   Stirling, Y ^b   Garrow, K ^b   Dickinson, C J ^b   Rose, G ^b   Miller, G J ^b   Peart, W S ^b   Breckenridge, A M ^b   Grahame Smith, D G ^b   Pocock, S J ^b   Zuhrie, S R ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULATION; AORTA RUPTURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DISSECTING ANEURYSM; DRUG EFFICACY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOSIS PREVENTION; UNITED KINGDOM;

EID: 0032562005     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11475-1     Document Type: Article

References (35)

1. 1 Meade TW, North WRS, Chakrabarti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i: 1050-54.
2. 2 Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-37.
3. 3 Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJM 1994; 87: 403-06.
4. 4 Meade TW, Stirling Y, Thompson SG, et al. An international and inter-regional comparison of haemostatic variables in the study of ischaemic heart disease. Int J Epidemiol 1986; 15: 331-36.
5. 5 Hirsh J, Poller L. Practical dosing consideration with warfarin and optimal therapeutic range. In: Oral anticoagulants. Eds: L Poller, J Hirsh. Arnold, Hodder Headline Group, London, 1996: 167-79.
6. 6 Meade TW. Oral anticoagulants in the secondary and primary prevention of myocardial infarction and coronary death. In: Oral anticoagulants. Eds: L Poller, J Hirsh. Arnold, Hodder Headline Group, London, 1996: 132-42.
7. 7 Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; ii: 989-94.
8. 8 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
9. 9 Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
10. 10 Antiplatelet Trialists' Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy. BMJ 1988; 296: 320-31.
11. 11 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
12. 12 Second International Study of Infarct Survival Collaborative Group. (ISIS-2.) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
13. 13 Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993; 329: 524-29.
14. 14 Hennekens CH, During JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749-56.
15. 15 Prichard PJ, Kitchingman GK, Walt RP, Daneshmend TK, Hawkey CJ. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ 1989; 298: 493-96.
16. 16 Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-41.
17. 17 Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleher C, Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988; 9: 836-43.
18. 18 Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemostas 1992; 68: 1-6.
19. 19 World Health Organisation Regional Office for Europe. Myocardial infarction community registers. Public Health in Europe, no5. Copenhagen: WHO, 1976.
20. 20 Medical Research Council working party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.
21. 21 O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 349-56.
22. 22 Steering Committee of the Physicians Study Research Group. Final report on the aspirin component of the ongoing physicians study. N Engl J Med 1989; 321: 129-35.
23. 23 Peto R, Grey R, Collins R, et al. Randomized trial of prophylatic daily aspirin in British male doctors. BMJ 1988; 296: 313-16.
24. 24 Roderick PJ, Brennan PJ, Meade TW. Do risk factors change in men at high risk of coronary heart disease? Observations on the effect of health promotion in primary care. J Cardiovasc Risk 1995; 2: 353-57.
25. 25 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995; 333: 1301-07.
26. 26 Stephens NG, Parsons A, Schofield PM, et al. A randomised controlled trial of vitamin E in patients with coronary disease; the Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-86.
27. 27 Committee of the Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; ii: 600-04.
28. 28 Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
29. 29 van Bergen PFMM, Jonker JJC, van Hout BA, et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995; 273: 925-28.
30. 30 Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed mini-dose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987; 295: 1309-12.
31. 31 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-38.
32. 32 Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389-96.
33. 33 Post Coronary Artery Bypass Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62.
34. 34 Lancaster T, Mant J, Singer DE. Stroke prevention in atrial fibrillation. BMJ 1997; 314: 1563-64.
35. 35 Peverill RE, Harper RW, Smolich JJ. CARS trial: warfarin and thrombin generation. Lancet 1997; 350: 1177-78.